NUS Stock Overview
Nu Skin Enterprises, Inc. develops and distributes beauty and wellness products worldwide.
Nu Skin Enterprises Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$33.37|
|52 Week High||US$56.76|
|52 Week Low||US$33.29|
|1 Month Change||-17.13%|
|3 Month Change||-25.38%|
|1 Year Change||-19.55%|
|3 Year Change||-19.80%|
|5 Year Change||-46.81%|
|Change since IPO||16.07%|
Recent News & Updates
Returns On Capital Signal Tricky Times Ahead For Nu Skin Enterprises (NYSE:NUS)
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Nu Skin Enterprises (NYSE:NUS) Is Due To Pay A Dividend Of $0.385
Nu Skin Enterprises, Inc. ( NYSE:NUS ) will pay a dividend of $0.385 on the 7th of September. This means the annual...
|NUS||US Personal Products||US Market|
Return vs Industry: NUS exceeded the US Personal Products industry which returned -33.8% over the past year.
Return vs Market: NUS exceeded the US Market which returned -23.2% over the past year.
|NUS Average Weekly Movement||4.5%|
|Personal Products Industry Average Movement||9.5%|
|Market Average Movement||6.8%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: NUS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: NUS's weekly volatility (5%) has been stable over the past year.
About the Company
Nu Skin Enterprises, Inc. develops and distributes beauty and wellness products worldwide. It provides skin care systems, including ageLOC Spa systems, ageLOC Transformation anti-aging skin care systems, and ageLOC LumiSpa skin treatment and cleansing devices; and ageLOC Boost, as well as a range of other cosmetic and personal care products. The company also offers ageLOC Youth nutritional supplements, ageLOC TR90 weight management and body shaping systems, LifePak nutritional supplements, ageLOC Meta nutritional supplements, and Beauty Focus Collagen+ skin care supplements, as well as other weight management products.
Nu Skin Enterprises Fundamentals Summary
|NUS fundamental statistics|
Is NUS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NUS income statement (TTM)|
|Cost of Revenue||US$635.68m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||2.25|
|Net Profit Margin||4.57%|
How did NUS perform over the long term?See historical performance and comparison
4.6%Current Dividend Yield
Is NUS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NUS?
Other financial metrics that can be useful for relative valuation.
|What is NUS's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does NUS's PE Ratio compare to its peers?
|NUS PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
EPC Edgewell Personal Care
HLF Herbalife Nutrition
USNA USANA Health Sciences
ELF e.l.f. Beauty
NUS Nu Skin Enterprises
Price-To-Earnings vs Peers: NUS is good value based on its Price-To-Earnings Ratio (14.8x) compared to the peer average (26.5x).
Price to Earnings Ratio vs Industry
How does NUS's PE Ratio compare vs other companies in the US Personal Products Industry?
Price-To-Earnings vs Industry: NUS is expensive based on its Price-To-Earnings Ratio (14.8x) compared to the US Personal Products industry average (14.5x)
Price to Earnings Ratio vs Fair Ratio
What is NUS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||14.8x|
|Fair PE Ratio||23x|
Price-To-Earnings vs Fair Ratio: NUS is good value based on its Price-To-Earnings Ratio (14.8x) compared to the estimated Fair Price-To-Earnings Ratio (23x).
Share Price vs Fair Value
What is the Fair Price of NUS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: NUS ($33.37) is trading below our estimate of fair value ($108.06)
Significantly Below Fair Value: NUS is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
How is Nu Skin Enterprises forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NUS's forecast earnings growth (20.7% per year) is above the savings rate (1.9%).
Earnings vs Market: NUS's earnings (20.7% per year) are forecast to grow faster than the US market (14.8% per year).
High Growth Earnings: NUS's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: NUS's revenue (2% per year) is forecast to grow slower than the US market (7.7% per year).
High Growth Revenue: NUS's revenue (2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NUS's Return on Equity is forecast to be high in 3 years time (20.9%)
Discover growth companies
How has Nu Skin Enterprises performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NUS has high quality earnings.
Growing Profit Margin: NUS's current net profit margins (4.6%) are lower than last year (8.4%).
Past Earnings Growth Analysis
Earnings Trend: NUS's earnings have grown by 4.9% per year over the past 5 years.
Accelerating Growth: NUS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: NUS had negative earnings growth (-52%) over the past year, making it difficult to compare to the Personal Products industry average (-4.8%).
Return on Equity
High ROE: NUS's Return on Equity (12.1%) is considered low.
Discover strong past performing companies
How is Nu Skin Enterprises's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: NUS's short term assets ($882.9M) exceed its short term liabilities ($384.1M).
Long Term Liabilities: NUS's short term assets ($882.9M) exceed its long term liabilities ($575.7M).
Debt to Equity History and Analysis
Debt Level: NUS's net debt to equity ratio (4.2%) is considered satisfactory.
Reducing Debt: NUS's debt to equity ratio has reduced from 60.7% to 45.4% over the past 5 years.
Debt Coverage: NUS's debt is well covered by operating cash flow (45.4%).
Interest Coverage: NUS's interest payments on its debt are well covered by EBIT (22.9x coverage).
Discover healthy companies
What is Nu Skin Enterprises's current dividend yield, its reliability and sustainability?
Dividend Score 5/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
|Nu Skin Enterprises Dividend Yield vs Market|
|Company (Nu Skin Enterprises)||4.6%|
|Market Bottom 25% (US)||1.7%|
|Market Top 25% (US)||4.7%|
|Industry Average (Personal Products)||1.3%|
|Analyst forecast in 3 Years (Nu Skin Enterprises)||4.6%|
Notable Dividend: NUS's dividend (4.61%) is higher than the bottom 25% of dividend payers in the US market (1.67%).
High Dividend: NUS's dividend (4.61%) is low compared to the top 25% of dividend payers in the US market (4.73%).
Stability and Growth of Payments
Stable Dividend: NUS's dividends per share have been stable in the past 10 years.
Growing Dividend: NUS's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonable payout ratio (67.5%), NUS's dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonable cash payout ratio (54.5%), NUS's dividend payments are covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ryan Napierski (48 yo)
Mr. Ryan S. Napierski has been Chief Executive Officer of Nu Skin Enterprises Inc. since September 1, 2021. Mr. Napierski has been the President of Nu Skin Enterprises Inc. since March 7, 2017 and has been...
CEO Compensation Analysis
|Ryan Napierski's Compensation vs Nu Skin Enterprises Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||US$5m||US$801k|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||US$4m||US$721k|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||US$2m||US$688k|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||US$3m||US$621k|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||n/a||n/a|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||US$3m||US$594k|
|Sep 30 2017||n/a||n/a|
|Jun 30 2017||n/a||n/a|
|Mar 31 2017||n/a||n/a|
|Dec 31 2016||US$4m||US$660k|
|Sep 30 2016||n/a||n/a|
|Jun 30 2016||n/a||n/a|
|Mar 31 2016||n/a||n/a|
|Dec 31 2015||US$4m||US$538k|
Compensation vs Market: Ryan's total compensation ($USD4.73M) is about average for companies of similar size in the US market ($USD5.58M).
Compensation vs Earnings: Ryan's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Experienced Management: NUS's management team is considered experienced (3.2 years average tenure).
Experienced Board: NUS's board of directors are seasoned and experienced ( 12.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: NUS insiders have only sold shares in the past 3 months.
Recent Insider Transactions
|07 Sep 22||SellUS$62,782||James Thomas||Individual||1,602||US$39.19|
|18 Aug 22||SellUS$257,290||Steve Hatchett||Individual||5,500||US$46.78|
|18 May 22||SellUS$1,001,915||Steven Lund||Individual||22,125||US$46.07|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Nu Skin Enterprises, Inc.'s employee growth, exchange listings and data sources
- Name: Nu Skin Enterprises, Inc.
- Ticker: NUS
- Exchange: NYSE
- Founded: 1984
- Industry: Personal Products
- Sector: Household
- Implied Market Cap: US$1.681b
- Shares outstanding: 50.38m
- Website: https://www.nuskin.com
Number of Employees
- Nu Skin Enterprises, Inc.
- 75 West Center Street
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|NUS||NYSE (New York Stock Exchange)||Yes||Class A Common Stock||US||USD||Nov 1996|
|NUS||DB (Deutsche Boerse AG)||Yes||Class A Common Stock||DE||EUR||Nov 1996|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/02 00:00|
|End of Day Share Price||2022/09/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.